Dr Henry Janssen, professor of medicine at the University of Toronto and chief of hepatology and director of the
Toronto Centre for Liver Disease at
Toronto General Hospital, says that the challenge will not be HBsAg and HBV loss but sustainment of that. “To get it sustained, we think that we need an immune modifier to get that done,” Janssen explains “So you have to tickle the immune response in such a way that it takes control over the virus, and that the virus doesn’t bounce back.